Soligenix is a late-stage biopharmaceutical company dedicated to developing and commercializing innovative products to treat rare diseases with unmet medical needs. Their expertise lies in the development of orphan and unmet medical need indications, encompassing preclinical, manufacturing, regulatory, and clinical aspects. Soligenix's product pipeline includes specialized biotherapeutics for diseases such as Cutaneous T-Cell Lymphoma (CTCL), Oral Mucositis, Pediatric Crohn's Disease, and Plaque Psoriasis.

They also focus on public health solutions, with programs aimed at infectious diseases and biodefense applications. One of their most advanced projects is a vaccination program to prevent ricin poisoning. Soligenix has received funding from notable organizations like NIH, BARDA, DTRA, and FDA.

With a commitment to addressing the challenges of rare disease treatment, Soligenix is poised to make a significant impact in the healthcare industry